Skip to content
lifestyle.washingtonguardian.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Jade Biosciences
Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 13, 2026
Jade Biosciences to Participate in Upcoming Conferences
November 3, 2026
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
October 21, 2026
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
September 30, 2026
Jade Biosciences to Participate in Upcoming Conferences
September 1, 2026
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 10, 2026
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
June 26, 2026
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 5, 2026
Jade Biosciences Announces Pricing of Public Offering of Common Stock
June 3, 2026
Jade Biosciences Announces Proposed Underwritten Public Offering
June 3, 2026
1
2
Next Page
→